Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance
FDA-2023-D-5259-0032Other
Comments
2
Last activity Jul 10, 2026
Deadline
15 days
Closes Aug 25, 2026
Net supportiSupport minus oppose · campaigns included
0%
0% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance
- Posted
- Jun 24, 2026
- Comment period
- Jun 24, 2026 – Aug 25, 2026
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 1 of 2 comments
50%· analysis in progress
Stance breakdown
0%
Net support
Other1Not yet analyzed1
Aggregates include form-letter campaigns. Excluding them, net support is 0% across organic comments.
Who commented
Breakdown by commenter type.
Individual
1
Not yet analyzed
1
Comments over time
Weekly arrivals, stacked by stance.
Posted Jun 24, 2026Deadline Aug 25, 2026
Jul 6Jul 20
Support0Oppose0Other1
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
0%
0%
100%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jul 20, 2026Comment from Progress Federal SolutionsAnalysis pending📎 AttachmentRead comment →
- Jul 10, 2026Comment from Souad MessahelOtherIndividual
The commenter is seeking clarification on the regulatory expectations and procedures for submitting Pre-IND and IND applications using a master protocol framework for multiple investigational drugs. They are asking for confirmation on whether this framework is permissible for evaluating multiple agents within a single disease program.
Read comment →